Slide 1: Exchange filing cover letter
29th January, 2021 (1) BSE Limited (2) National Stock Exchange of India Limited Listing Department, Listing Department Phiroze Jeejeebhoy Towers, Exchange Plaza, 5th floor, Dalal Street, Plot no. C/1, G Block, Mumbai 400 001 Bandra Kurla Complex, Bandra (East), Mumbai - 400 051 Scrip Code: 500087 Sc
Slide 2: Investor Presentation Q3FY21
CLICK TO EDIT MASTER TITLE STYLE Investor Presentation Q3FY21 29-1-2021
Slide 3: Disclaimer
DISCLAIMER CLICK TO EDIT MASTER TITLE STYLE Except for the historical information contained herein, statements in this presentation and the subsequent discussions may constitute "forward-looking statements". These forward-looking statements involve a number of risks, uncertainties including impact o
Slide 4: In Q3, we continued our efforts globally in combating Covid-19
In Q3, we continued our efforts globally in combating Covid-19 and CLICK TO EDITdelivering onSTYLE MASTER TITLE our promise of ‘Caring for life’ Patients Physicians Employees ❖ 2 lac+ severe COVID patients ❖ 600+ virtual conferences & ❖ Hybrid return to office served during the quarter; 4 webinars e
Slide 5: We commissioned the largest open access solar power plant under group captive scheme in Maharashtra
We commissioned the largest open access solar power plantCLICK under group TO EDIT captive MASTER scheme in Maharashtra TITLE STYLE Largest open access solar power plant in the state ❖ 30 MW solar group captive project in Tuljapur, Maharashtra spread across an area of 11 acres ❖ Project in partnersh
Slide 6: Strong demand, sustained cost optimization and operational excellence drives Q3 performance
Strong demand, sustained cost optimization and operational excellence CLICK TO EDIT drives MASTER TITLE STYLEQ3 performance One India strategy progressing well Solid traction in top consumer brands Overall Revenue (YoY Growth) Overall 22% 6th Consecutive quarter revenue of double-digit growth in 15%
Slide 7: Strong balance sheet and robust free cash flow generation
Strong balance sheet and robust free cash flow generation CLICK TO EDIT MASTER TITLE STYLE Net Debt (INR Cr) Net Debt / Equity Cash Balances1 807 0.05 (INR Cr) 2,746 Net cash Net cash positive positive position position 2,009 (939) (0.05) Mar'20 Dec'20 Mar'20 Dec'20 Mar'20 Dec'20 ▪ Continued governa
Slide 8: Financial Performance – Q3FY21
Financial Performance – Q3FY21 CLICK TO EDIT MASTER TITLE STYLE Revenues INR 5,169 Cr 18% YoY EBITDA2 INR 1,281 Cr │ 24.8% 69% YoY Q3 FY21 (Consolidated) Revenue1 Break-up Actuals Others, vs Q3 FY 20 API, 4% (Rs Cr) 1% Europe, 5% Total Revenue from 5,169 18% Emerging Operations Mkts, 9% EBITDA2 1,28
Slide 9: One India (Rx + Gx + CHL): Consistent execution driving growth across businesses
One India (Rx + Gx+ CHL1): Consistent execution driving growth across CLICK TO EDITbusinesses MASTER TITLEinSTYLE India Key Business Highlights One India Q3 Y-o-Y Prescription business ❖ Growth led by covid-19 portfolio, healthy traction in Rs. Cr respiratory and chronic therapies, recovery in hospi
Slide 10: Solid traction across top consumer brands
Solid traction across top consumer brands CLICK TO EDIT MASTER TITLE STYLE Anchor consumer brands Emerging consumer brands #1 18.6% Pain Relief Category market share in Dec’20 8% (YTD YoY growth) 46% (YTD YoY growth) 38% #1 98.1% (YTD YoY growth) NRT Category market share in Nov’20 14% (YTD YoY grow
Slide 11: SAGA: South Africa, Sub-Saharan Africa and Cipla Global Access
SAGA1: South Africa, Sub-Saharan Africa and Cipla Global Access CLICK TO EDIT MASTER TITLE STYLE Key Business Highlights Q3 Y-o-Y South Africa ❖ Overall business in-line with last year for the quarter in ZAR terms $ Mn Private 11% Tender 8% (9MFY21 YoY growth (9MFY21 YoY growth market market 45 in Z
Slide 12: North America: Momentum continues driven by traction in new launches
North America: Momentum continues driven by traction in newCLICK launches TO EDIT MASTER TITLE STYLE Key Business Highlights Q3 Y-o-Y US Generics ramp-up continues ❖ Continued expansion in market share for Albuterol and traction in other $ Mn assets along with growth in the institutional channel ❖ I
Slide 13: ANDA Portfolio & Pipeline (As on 31st December 2020)
ANDA1 Portfolio & Pipeline (As on 31st December 2020) CLICK TO EDIT MASTER TITLE STYLE Total ANDAs 165 19 66 250 22 56 9 4 21 78 4 3 1 10 37 5 Approved ANDAs Tentatively Approved ANDAs Under Approval ANDAs 2 Cipla Ltd PEFPAR Invagen Partnered ANDAs 1 Does not include Vet product ANDAs 2 PEPFAR appro
Slide 14: Emerging Markets, Europe and API
Emerging Markets, Europe and API CLICK TO EDIT MASTER TITLE STYLE Emerging Markets Europe API Q3 Y-o-Y Q3 Y-o-Y Q3 Y-o-Y $ Mn 66 $ Mn 34 $ Mn 46% 28% 18% 27 45 27 23 Q3FY20 Q3FY21 Q3FY20 Q3FY21 Q3FY20 Q3FY21 Key Business Highlights Key Business Highlights Key Business Highlights ❖ Consistent in-mark
Slide 15: Our priorities include
Our priorities include CLICK TO EDIT MASTER TITLE STYLE Maintain market beating growth in large branded and unbranded generic franchises of India, South Africa and augment consumer wellness franchise Expanding lung leadership globally and maximising value opportunity in US complex generics by priori
Slide 16: Thank You
Thank You Registered Office : Cipla Limited, Cipla House, Peninsula Business Park, Ganpatrao Kadam Marg, Lower Parel, Mumbai 400 013 For any queries, please contact Naveen Bansal Investor.Relations@cipla.com For more information please visit www.cipla.com